Sanofi: Stifel upgrades stock

(CercleFinance.com) - Stifel has upgraded Sanofi shares from 'hold' to 'buy', with a price target raised from E95 to E109, following an adjustment in the value of the pipeline in its model for the French healthcare group.


The broker says it is "reasonably optimistic that Sanofi can display a cycle of strong short-term growth driven by Dupixent and Beyfortus (11% EPS CAGR over 2024-27), followed by an improved pipeline delivery".


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.